Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22123174 | 1.00 | MMP2 (0.44) | MMP2ANPEPTSHRMAPTBRD4 | |
| SCHEMBL29155483 | 1.00 | MMP2 (0.44) | MMP2ANPEPTSHRMAPTBRD4 | |
| SCHEMBL693749 | 0.86 | TSHR (0.41) | TSHRMAPTBRD4TP53SMN1; SMN2 | |
| SCHEMBL693748 | 0.86 | TSHR (0.41) | TSHRMAPTBRD4TP53SMN1; SMN2 | |
| SCHEMBL19656301 | 0.83 | OPRK1 (0.38) | MMP2ANPEPTSHRMAPTBRD4 | |
| SCHEMBL30546726 | 0.83 | MAPT (0.43) | TSHRMAPTBRD4TP53SMN1; SMN2 | |
| SCHEMBL29155481 | 0.79 | MAPT (0.45) | TSHRMAPTGAAPOLB | |
| SCHEMBL29155482 | 0.79 | MAPT (0.45) | TSHRMAPTGAAPOLB | |
| SCHEMBL23163268 | 0.79 | MAPT (0.45) | TSHRMAPTGAAPOLB | |
| SCHEMBL22122675 | 0.79 | TP53 (0.40) | MMP2ANPEPTSHRMAPTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | TOLREMO THERAPEUTICS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-20260076967-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| US-12478624-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | TOLREMO THERAPEUTICS AG (CH) | 2025-11-25 | — | — | US | disclosed |
| US-12472179-B2 | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | TOLREMO THERAPEUTICS AG (CH) | 2025-11-18 | — | — | US | disclosed |
| US-20250243191-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| CN-115701996-B | Combination of CBP/p300 bromodomain inhibitors and EGFR inhibitors for the treatment of EGFR mutant NSCLC | 托雷莫治疗股份公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20240327394-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2024-10-03 | — | — | US | disclosed |
| CN-114728934-B | Heterocyclic derivatives, pharmaceutical compositions and their use for treating or ameliorating cancer | 托雷莫治疗股份公司 | 2024-08-27 | — | — | CN | disclosed |
| EP-4320109-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | Tolremo Therapeutics AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| CN-117355512-A | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | 托雷莫治疗股份公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4171557-A1 | COMBINATION OF A CBP/P300 BROMODOMAIN INHIBITOR AND A KRAS INHIBITOR FOR THE TREATMENT OF CANCER | Tolremo Therapeutics AG (CH) | 2023-05-03 | — | — | EP | disclosed |
| CN-115996717-A | Combination of CBP/P300 bromodomain inhibitors and KRAS inhibitors for the treatment of cancer | 托雷莫治疗股份公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230064948-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| CN-115701996-A | Combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for the treatment of EGFR mutant NSCLC | 托雷莫治疗股份公司 | 2023-02-14 | — | — | CN | disclosed |
| WO-2022214606-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2022-10-13 | — | — | WO | disclosed |
| EP-4041399-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | Tolremo Therapeutics AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| CN-114728934-A | Heterocyclic derivatives, pharmaceutical compositions and their use for treating or ameliorating cancer | 托雷莫治疗股份公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021260109-A1 | A COMBINATION OF A CBP/p300 BROMODOMAIN INHIBITOR AND AN EGFR INHIBITOR FOR USE IN TREATING EGFR-MUTANT NSCLC | TOLREMO THERAPEUTICS AG (CH) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021260111-A1 | COMBINATION OF A CBP/P300 BROMODOMAIN INHIBITOR AND A KRAS INHIBITOR FOR THE TREATMENT OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021260110-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF FIBROTIC DISEASE | TOLREMO THERAPEUTICS AG (CH) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12472179-B2 | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | EP300, KRAS, BRD4 | MMP2 1410/4885ANPEP 3498/4885TSHR 3259/4885 |
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | SLC10A1, MAPT, SLC6A6 | MMP2 2535/4885ANPEP 4649/4885TSHR 3591/4885 |
| US-20260076967-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, XDH, SLC10A1 | MMP2 2715/4885ANPEP 4541/4885TSHR 1196/4885 |
| US-20240327394-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TP53, MAPT, SLC10A1 | MMP2 3408/4885ANPEP 4245/4885TSHR 4220/4885 |
| US-20230064948-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | SLC10A1, SLC6A6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MMP2 2146/4885ANPEP 4089/4885TSHR 3749/4885 |
| US-12478624-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | SLC10A1, SLC6A6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MMP2 2146/4885ANPEP 4089/4885TSHR 3749/4885 |
| US-20250243191-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TP53, MAPT, SLC10A1 | MMP2 3408/4885ANPEP 4245/4885TSHR 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.